Skip to main content

Table 2 Baseline demographic data for all treatment groups: European data

From: Interleukin-6: a new therapeutic target

  Treatment  
Characteristics 2 mg/kg (n = 53) 4 mg/kg (n = 54) 8 mg/kg (n = 52) 2 mg/kg + MTX (n = 52) 4 mg/kg + MTX (n = 49) 8 mg/kg + MTX (n = 50) MTX (n = 49) All groups (n = 359)
Age (years) 52.2 49.3 50.1 49.2 50.2 50.1 50.9 50.3
Sex (male/female) 9/44 13/41 14/38 7/45 12/37 11/39 11/38 77/282
Duration of RA (years) 9.19 9.79 9.21 9.33 7.82 10.62 11.24 -
TJC (28) 15 15 15 15 13 15 16 15
SJC (28) 11 11 12 11 11 11 12 11
ESR (mm/hour) 39a 41 39b 45c 40 39d 43 41
CRP (mg/l) 26a 19 22b 28c 31 24d 32 27
DAS28 6.48a 6.55 6.43b 6.58c 6.34 6.47d 6.75  
RF positive (n) 44 39 43 46 38 40 47  
  1. an = 52; bn = 51; cn = 50; dn = 49. CRP, C-reactive protein; DAS28, Disease Activity Score; ESR, erythrocyte sedimentation rate; MTX, methotrexate; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, total joint count. Reproduced, with permission, from [13].